Why Most First Launches Fail

A first commercial launch is one of the most unforgiving transitions in life sciences. The company moves from proving a molecule’s promise to proving an enterprise can deliver—reliably, compliantly, and at scale.

Most first launches do not “fail” because the product is weak. They fail because leadership underestimates the integrated complexity of commercialization: manufacturing and quality maturity, market access realities, field execution, omnichannel engagement, patient services, and post-approval obligations—running concurrently, on immovable timelines.

The predictable result is underperformance in the only two metrics that matter at launch: speed to first patient and repeatable demand capture without operational disruption.

Failure Mode 1: The launch plan assumes approvals are the finish line

Many first-time commercial organizations behave as though regulatory approval is the final milestone. In reality, approval is the starting gun.

Immediately after approval, the organization must execute under heightened visibility:

• stable supply and batch release discipline,
  
  
• medical information and safety workflows,
  
  
• complaint handling and quality reporting,
  
  
• pricing, contracting, and reimbursement mechanics,
  
  
• field deployment and compliant promotion,
  
  
• inventory positioning and distribution,
  
  
• real-world evidence and post-approval commitments.
  
  

Teams that treat approval as “end of project” typically miss the operating model required to run a commercial enterprise.

Failure Mode 2: CMC and Quality readiness are assumed—until they break

First launches fail frequently on the operational backbone:

• insufficient validated capacity,
  
  
• fragile raw material supply,
  
  
• immature deviation/CAPA discipline,
  
  
• inadequate vendor oversight (CDMO governance),
  
  
• underpowered stability data,
  
  
• change control that cannot keep pace with scale.
  
  

If Quality and CMC are not integrated into commercial decision-making early, the company discovers late-stage constraints when changes are expensive, timelines are fixed, and reputational risk is high.

In first launches, supply instability does not simply delay revenue. It damages credibility with prescribers, payers, patients, and partners—often permanently.

Failure Mode 3: Market access is treated as a “pricing exercise,” not a value system

Launches fail when payer reality collides with internal assumptions.

Common access breakdowns include:

• value story not aligned to payer decision criteria,
  
  
• weak endpoints or insufficient differentiation narrative,
  
  
• inadequate HEOR plan, poor evidence sequencing,
  
  
• misaligned pricing vs. clinical benefit perception,
  
  
• reimbursement pathways not operationalized (coding, coverage, claims),
  
  
• hub and patient services under-designed or delayed.
  
  

The net effect is slow uptake, high abandonment, and a field team that cannot convert interest into treated patients.

Failure Mode 4: The field is deployed before the system can support it

Inexperienced organizations often “hire the field” early because it is visible and comforting. But a field force without a functional system produces noise, not uptake.

Launch execution requires a tightly integrated engine:

• target list and segmentation,
  
  
• compliant messaging and MLR cadence,
  
  
• CRM hygiene and omnichannel coordination,
  
  
• medical/scientific exchange protocols,
  
  
• payer pull-through processes,
  
  
• patient support services with clear escalation.
  
  

When this engine is immature, the organization burns cash and erodes confidence internally—while losing the narrow window where momentum compounds.

Failure Mode 5: Medical Affairs is underpowered or positioned too late

Medical Affairs is frequently mis-scoped in first launches, despite being central to:

• scientific credibility pre- and post-launch,
  
  
• KOL mapping and engagement strategy,
  
  
• congress and publication planning,
  
  
• medical education and insights loop,
  
  
• medical information and evidence generation.
  
  

When Medical Affairs is not architected early, the organization struggles to build trust in the scientific community—especially in specialty, rare disease, and complex modalities where peer confidence drives adoption.

Failure Mode 6: The operating model cannot handle cross-functional trade-offs

A first launch is a constant series of trade-offs:

• demand generation vs. supply constraints,
  
  
• access concessions vs. brand positioning,
  
  
• speed vs. compliance,
  
  
• geographic expansion vs. operational capacity.
  
  

Launches fail when there is no clear governance to make enterprise decisions quickly and consistently. The symptoms are familiar:

• repeated “alignment meetings” without decisions,
  
  
• functional leaders optimizing locally,
  
  
• late-stage escalations,
  
  
• confusion over decision rights,
  
  
• critical paths hidden in silos.
  
  

A CEO-grade launch requires explicit governance, decision velocity, and accountability—well before approval.

Failure Mode 7: Metrics reward activity, not outcomes

First-time companies often track what is easy, not what is decisive.

Activity metrics (calls, emails, impressions) are insufficient if they do not connect to launch outcomes:

• time to first treated patient,
  
  
• payer coverage velocity and quality,
  
  
• prescription conversion and abandonment,
  
  
• inventory turns and service levels,
  
  
• complaint rates and quality signals,
  
  
• adherence and persistence signals.
  
  

If leadership cannot see the true constraint in near real time, teams optimize in the wrong place and lose months that cannot be recovered.

The “Launch-Ready” Playbook: What Winners Do Differently

1) Build the launch as a system, not a function

Launch excellence is not “Commercial’s job.” It is an enterprise operating system spanning:

• Quality, CMC, Tech Ops
  
  
• Regulatory and Safety
  
  
• Market Access, HEOR, Medical Affairs
  
  
• Commercial Ops, Field, Marketing
  
  
• Finance, Legal/Compliance, IT/Data
  
  
• Patient services and distribution partners
  
  

Organizations that win treat launch readiness like a cross-functional product itself—with a dedicated owner and measurable outputs.

2) Establish governance early with explicit decision rights

High-performing first launches define:

• a single accountable launch leader,
  
  
• decision forums (weekly operating + executive steering),
  
  
• clear escalation paths,
  
  
• one integrated critical path,
  
  
• one source of truth for risk and mitigation.
  
  

3) Staff for experience, not headcount

The most common talent error is hiring “good people” without first-launch scar tissue in the roles that carry irreversible risk.

Launch-critical leaders typically include:

• Head/VP Market Access (with payer and contracting depth)
  
  
• Head/VP Medical Affairs (KOL strategy + evidence)
  
  
• Head/VP Quality (inspection readiness + commercial quality systems)
  
  
• Head/VP CMC/Tech Ops (scale-up, tech transfer, vendor governance)
  
  
• Commercial Operations lead (forecasting, CRM, omnichannel, incentive comp)
  
  
• Patient Services / Hub lead (access operations and experience design)
  
  

4) Pressure-test the launch with scenario planning

Before approval, leadership should pressure-test:

• constrained supply scenarios,
  
  
• delayed coverage scenarios,
  
  
• label limitations,
  
  
• competitive response,
  
  
• adverse event visibility,
  
  
• manufacturing changes and comparability needs.
  
  

Scenario planning reduces panic decisions and helps teams pre-commit to trade-offs.

A Practical Timeline: 180 Days to Launch (What “Ready” Looks Like)

T-180 to T-120 (Build the engine)

• finalize governance, critical path, and risk register
  
  
• lock payer value story and evidence plan
  
  
• confirm supply strategy, release process, and CDMO governance cadence
  
  
• define patient services design and distribution model
  
  

T-120 to T-60 (Operationalize execution)

• complete MLR workflows and content readiness
  
  
• finalize field structure, territories, and targeting
  
  
• implement dashboards tied to treated patients and access velocity
  
  
• validate end-to-end order-to-cash and reimbursement workflows
  
  

T-60 to Approval (Stress test)

• run “day 1” simulations (orders, hub intake, escalations, returns, complaints)
  
  
• validate inventory positioning and service levels
  
  
• confirm medical information, PV, and complaint handling readiness
  
  
• finalize launch command center and escalation routes
  
  

Approval to T+90 (Stabilize and scale)

• manage demand vs. supply trade-offs
  
  
• tighten pull-through, reduce abandonment
  
  
• optimize targeting and messaging based on real-world signals
  
  
• expand access breadth without creating operational debt
  
  

CEO Checklist: Is Your First Launch at Risk?

If you answer “no” to any of these, you likely have a launch risk that will surface late:

1. Do we have a single integrated critical path across functions?
   
   
2. Are Quality and CMC represented in commercial trade-off decisions?
   
   
3. Is payer strategy operationalized (coverage, claims workflow, hub readiness)?
   
   
4. Do we know our real constraint: supply, access, awareness, or conversion?
   
   
5. Are metrics tied to treated patients, not activity?
   
   
6. Do we have leaders with first-launch experience in the highest-risk seats?
   
   
7. Can we run “day 1” simulations end-to-end without workarounds?
   
   

Conclusion: First launches fail from preventable execution gaps

The first launch is where companies stop being “a promising asset” and become “a reliable enterprise.” Failure usually comes from predictable, preventable breakdowns: operational fragility, access reality, weak governance, underpowered medical and quality systems, and leadership gaps in the roles that matter most.

The good news is that first-launch failure is rarely mysterious. It is largely a consequence of decisions made too late—about operating model, talent, and cross-functional accountability.